ADVERTISEMENT

Conference Report

ASCO 2022 – Circulating tumour DNA: is this the light to guide adjuvant therapy in colon cancer?

Cristina Ferrario — Agenzia Zoe   |   06 June 2022

Takeaway

  • In patients with stage II colon cancer, an approach based on circulating tumour DNA (ctDNA) reduces the use of adjuvant chemotherapy without compromising recurrence risk.
  • ctDNA-positive patients are likely to benefit from adjuvant chemotherapy, while ctDNA-negative patients are not.

Why this matters

  • Surgery can cure more than 80% of...

          

November Challenge

Ends in 1d 7h
left
right

Topic Challenges

left
right